DDI

CompletedPhase 1

Drug Interaction Study Between AZD3480 and Warfarin

A Single-Centre, Double Blind, Randomized, Two-Way Cross-Over Study of Repeated Doses of AZD3480 and Single Dose of Warfarin to Evaluate the Pharmacokinetic Interaction of AZD3480 and Warfarin and the Effect of AZD3480 Pharmacodynamic in Healthy Male Subjects (Phase I

Lead sponsor

AstraZeneca

Asset

AZD3480

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Alzheimer’s disease

Key I/E criteria

•Age 18-45•Male

Primary endpoint

•PK variables

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDD3690C00014

SecondaryEudraCt nr 2007-004756-37

NCT IDNCT00689637

Timeline

Milestones

Study start2007-09 (month precision)

Study first posted2008-06-03estimated

Study completion2009-02actual (month precision)

Last update posted2009-07-02estimated

Assets

Drug assets

AZD3480

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age45 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•Provision of signed written informed consent

•Clinically normal physical findings and laboratory values

Exclusion criteria

•Clinically significant illness or clinically relevant trauma within three weeks before the first dose

•History of clinically significant disease

•Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Other (unclassified)

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Safety variables (adverse events, blood pressure, pulse, safety lab)

Time frame:During the whole treatment period

event count, event

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

PK variables

Time frame:Frequent sampling occasions during days 5 and 6

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.